• Species Reactivity

  Mouse

• Specificity

  Detects mouse TGF-beta RIII in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross‑reactivity with recombinant human TGF‑ beta  sRII and recombinant mouse TGF‑ beta  RII is observed.

• Source

  Polyclonal Goat IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant mouse TGF‑ beta  RIII    
  Gly23-Thr785    
  Accession # NP_035708

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Endotoxin Level

  <0.50 EU per 1 μg of the antibody by the LAL method.  

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  0.1 µg/mL

  Recombinant Mouse TGF-beta  RIII (Catalog # )

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.2 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TGF-beta RIII

Transforming growth factor beta receptor III (TGF-beta RIII; also betaglycan) is a ubiquitously expressed, 280 kDa type I transmembrane proteoglycan member of the TGF-beta superfamily of proteins (1). Mouse TGF-beta RIII is synthesized as an 850 amino acid (aa) precursor that consists of a 22 aa signal sequence, a 763 extracellular domain (ECD), a 23 aa transmembrane region, and a 42 aa cytoplasmic tail. The large ECD contains heparan sulfate and chondroitin sulfate glycosaminoglycans, five potential N-linked glycosylation sites, and a zona pellucida-like domain from residues 454‑731 (1, 2). The short cytoplasmic domain is rich in serine and threonine, but has no discernible signaling structure typical of receptor kinases (2). Proteolysis at one of two potential juxtamembrane cleavage sites (Lys743Lys and Leu750AlaValVal) allows cells to release TGF-beta RIII in a soluble form (1, 2). Mouse TGF-beta RIII shares 94%, 82%, 80%, and 67% aa sequence identity with rat, human, porcine, and chicken TGF-beta RIII, respectively (2). In all of these species, TGF beta RIII contains 17 cysteines that are 100% conserved (2). TGF-beta RIII binds with high affinity to TGF-beta 1, TGF-beta 2, and TGF-beta 3 isoforms (1). TGF-beta RIII functions by binding, and then "presenting" ligand to TGF-beta type II receptors (1, 3). It also functions to limit ligand availability to the receptor via proteolysis which releases the soluble form of TGF beta RIII along with any bound factors, making them inaccessible to cell-surface receptors (1, 3). TGF-beta RIII can therefore enhance or inhibit cell signaling. TGF-beta RIII has been shown to play an essential role in the formation of the atrioventricular cushion and coronary vessels during development of the heart (4‑6). TGF beta RIII also plays a role in many cancers. Increased expression of TGF beta RIII is found in higher grade lymphomas, and reduced expression of TGF beta RIII is found with advanced stage neuroblastomas and ovarian carcinomas (4, 7‑9). Low TGF-beta RIII expression also correlates with higher grade among a cohort of breast cancers (4, 10). Additionally, overexpression of TGF-beta RIII in MDA-231 human breast cancer cells and DU145 prostate cancer cells results in decreased tumor invasion in vitro and in vivo (4, 11, 12).

• References:

1. Kolodziejczyk, S.M. and B.K. Hall (1996) Biochem. Cell Biol. 74:299.

2. Ponce-Castaneda, M.V. et al. (1998) Biochim. Biophys. Acta 1384:189.

3. Lopez-Casillas, F. et al. (1993) Cell 73:1435.

4. Criswell, T.L. and C.L. Arteaga (2007) J. Biol. Chem. 282:32491.

5. Brown, C.B. et al. (1999) Science 283:2080.

6. Compton, L.A. et al. (2007) Circ. Res. 101:784.

7. Woszczyk, D. et al. (2004) Med. Sci. Monit. 10:CRIII3.

8. Bristow, R.E. et al. (1999) Cancer 85:658.

9. Iolascon, A. et al. (2000) Br. J. Cancer 82:1171.

10. Dong, M. et al. (2007) J. Clin. Invest. 117:206.

11. Turley, R.S. et al. (2007) Cancer Res. 67:1090.

12. Sun, L. and  C. Chen (1997) J. Biol. Chem. 272:25367.

• Long Name:

  Transforming Growth Factor beta Receptor III

• Entrez Gene IDs:

  7049 (Human); 21814 (Mouse); 29610 (Rat)

• Alternate Names:

  betaglycan proteoglycan; Betaglycan; BGCAN; TBRIII; TGF-beta receptor type 3; TGF-beta receptor type III; TGF-beta RIII; TGFbetaRIII; TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta receptor III; transforming growth factor beta receptor type 3; transforming growth factor, beta receptor III (betaglycan, 300kDa); transforming growth factor, beta receptor III